XTX Topco Ltd Invests $389,000 in PROCEPT BioRobotics Co. (NASDAQ:PRCT)

XTX Topco Ltd acquired a new position in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 4,827 shares of the company's stock, valued at approximately $389,000.

A number of other large investors have also recently made changes to their positions in PRCT. FMR LLC raised its stake in shares of PROCEPT BioRobotics by 11.9% during the 4th quarter. FMR LLC now owns 8,159,208 shares of the company's stock valued at $656,979,000 after buying an additional 866,328 shares during the last quarter. Vanguard Group Inc. lifted its holdings in PROCEPT BioRobotics by 6.1% in the fourth quarter. Vanguard Group Inc. now owns 5,140,426 shares of the company's stock valued at $413,907,000 after acquiring an additional 297,075 shares during the period. Alliancebernstein L.P. boosted its position in PROCEPT BioRobotics by 14.2% in the 4th quarter. Alliancebernstein L.P. now owns 1,752,478 shares of the company's stock worth $141,110,000 after purchasing an additional 218,148 shares in the last quarter. Wellington Management Group LLP boosted its position in PROCEPT BioRobotics by 38.8% in the 4th quarter. Wellington Management Group LLP now owns 1,490,952 shares of the company's stock worth $120,051,000 after purchasing an additional 416,819 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of PROCEPT BioRobotics by 5.2% during the 4th quarter. Geode Capital Management LLC now owns 1,164,037 shares of the company's stock worth $93,751,000 after purchasing an additional 57,449 shares during the period. 89.46% of the stock is owned by hedge funds and other institutional investors.

PROCEPT BioRobotics Price Performance

Shares of PROCEPT BioRobotics stock traded down $0.07 during trading hours on Friday, reaching $52.49. 1,973,062 shares of the company's stock were exchanged, compared to its average volume of 809,071. The business has a fifty day moving average of $57.74 and a two-hundred day moving average of $73.98. The company has a market capitalization of $2.88 billion, a P/E ratio of -26.92 and a beta of 1.09. The company has a quick ratio of 5.07, a current ratio of 6.02 and a debt-to-equity ratio of 0.21. PROCEPT BioRobotics Co. has a 1 year low of $47.04 and a 1 year high of $103.81.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last issued its earnings results on Thursday, April 24th. The company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.04. PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. The business had revenue of $69.16 million for the quarter, compared to analysts' expectations of $65.39 million. As a group, research analysts predict that PROCEPT BioRobotics Co. will post -1.75 earnings per share for the current fiscal year.

Insider Buying and Selling

In other PROCEPT BioRobotics news, CFO Kevin Waters sold 733 shares of PROCEPT BioRobotics stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total transaction of $41,824.98. Following the completion of the sale, the chief financial officer now directly owns 107,991 shares in the company, valued at $6,161,966.46. This trade represents a 0.67 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Reza Zadno sold 5,475 shares of the company's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total transaction of $312,403.50. Following the completion of the transaction, the chief executive officer now owns 173,070 shares in the company, valued at approximately $9,875,374.20. This represents a 3.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 6,455 shares of company stock worth $368,322. Insiders own 17.40% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on PRCT shares. Truist Financial lowered their price target on shares of PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating on the stock in a report on Friday, April 11th. Morgan Stanley lowered their price target on PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 26th. Finally, Bank of America reduced their target price on PROCEPT BioRobotics from $104.00 to $84.00 and set a "buy" rating for the company in a research note on Friday. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $90.00.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).